% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Knauf:153915,
      author       = {W. Knauf and G. Dingeldein and R. Schlag and M. Welslau and
                      T. Moehler and T. Terzer$^*$ and S. Walter and H.
                      Goldschmidt and M.-S. Raab and B. t. group},
      title        = {{F}irst-line therapy with
                      {B}endamustine/{P}rednisone/{B}ortezomib ({BPV}) - {A}
                      {GMMG} trial for non-transplant eligible symptomatic
                      multiple myeloma patients.},
      journal      = {European journal of haematology},
      volume       = {105},
      number       = {2},
      issn         = {1600-0609},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2020-00525},
      pages        = {116-125},
      year         = {2020},
      note         = {2020 Aug;105(2):116-125},
      abstract     = {The German-speaking Myeloma Multicenter Group (GMMG)
                      conducted this trial to investigate efficacy and safety of
                      the 3-drug-combination bendamustine/prednisone/bortezomib
                      (BPV) as first-line therapy for elderly patients with
                      multiple myeloma (MM).Elderly MM patients requiring
                      first-line therapy and not eligible for intensive treatment
                      were enrolled in this phase IIb multicenter study. Patients
                      were treated with BPV regimen for a maximum of 9 cycles.46
                      patients were included into the trial with a median age of
                      76 years. 19 patients had renal impairment at baseline. The
                      ORR was $76.5\%,$ the median progression free survival 25
                      months and overall survival at 24 month $83.3\%.$ The
                      clinical benefit rate (CBR) including MR was $91.2\%.$ In
                      patients with renal impairment at baseline a renal response
                      was observed in 11 pts. with complete recovery of the renal
                      function in 6 patients. The most frequent CTC grade 3/4 AEs
                      experienced by patients were hematological $(17.5\%)$ and
                      infectious $(9.8\%)$ complications. No new safety signals
                      were observed for the study drugs under investigation.BPV
                      may serve as a first-line regimen for transplant ineligible
                      elderly MM patients in particular for patients with renal
                      impairment requiring a fast and durable renal response.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32155662},
      doi          = {10.1111/ejh.13409},
      url          = {https://inrepo02.dkfz.de/record/153915},
}